Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

Frankie Ann Holmes, MD
Published: Friday, Sep 01, 2017



Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

There will always be patients who do not choose to receive chemotherapy for tumors that are too large to remove by surgery, states Holmes. Some fast-growing tumors in select breast cancer subtypes may respond to deprivation of estrogen more than chemotherapy, explains Holmes.

SELECTED
LANGUAGE


Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

There will always be patients who do not choose to receive chemotherapy for tumors that are too large to remove by surgery, states Holmes. Some fast-growing tumors in select breast cancer subtypes may respond to deprivation of estrogen more than chemotherapy, explains Holmes.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x